In the prevention of inflammation‐driven colorectal cancer, RES suppresses the proinflammatory T‐cell response by reducing Th1 and Th17 cell populations while enhancing the presence of anti‐inflammatory CD4+ FOXP3+ Tregs and CD4+ IL‐10+ cells [134]. The gene discussed is CD4; the disease is colorectal cancer.